Efficacy And Safety Of Butylphthalein Injection In Treatment With Acute Large-area Cerebral Infarction

ObjectiveTo investigate the efficacy and safety of butylphthalide injection in the treatment of acute large-area cerebral infarction.Methods105 patients with acute large-area cerebral infarction were selected as the study subjects.The patients were divided into control group(n=52)and observation group(n=53)according to the random number table method,50 cases in each group.The control group was given routine treatment.The observation group was treated with butylphthalide injection on the basis of the control group.Two weeks was a course of treatment.The levels of serum C-reactive protein(CRP),interleukin-6(IL-6),and tumor necrosis factor-α(TNF-α)before and after treatment were compared between the two groups.Levels,serum neuron specific enolase(NSE)levels,serum S100βprotein levels,national institutes of health stroke scale(NIHSS)score,Activities of daily living(ADL)scale scores,clinical efficacy and adverse reactions.ResultsAfter treatment,the NIHSS scores in the observation group and the control group were(10.5±2.6)score and(15.8±3.2)score,respectively,which were significantly lower than before treatment(P<0.05);and the NIHSS score was significant in the observation group after treatment.Lower than the control group(P<0.05).After treatment,the ADL scores of the observation group and the control group were(78.9±11.4)score and(69.2±12.5)score,respectively,which were significantly higher than before treatment(P<0.05);and the ADL scores were significantly higher in the observation group after treatment.Control group(P<0.05).After treatment,serum NSE levels in the observation and control groups were(8.5±2.3)μg/L and(10.2±1.6)μg/L,respectively,which were significantly lower than before treatment(P<0.05);The level of serum NSE was significantly lower than that of the control group(P < 0.05).After treatment,serum S100β levels in the observation and control groups were(0.14±0.08)μg/L and(0.37±0.12)μg/L,respectively,which were significantly lower than before treatment(P<0.05);The level of serum S100β was significantly lower than that of the control group(P<0.05).After treatment,serum CRP levels in the observation and control groups were(10.4±3.9)mg/L and(16.2±4.4)mg/L,respectively,which were significantly lower than before treatment(P < 0.05);The level of serum CRP was significantly lower than that of the control group(P<0.05).After treatment,serum IL-6 levels in the observation group and the control group were(24.1±8.6)ng/L and(33.2±11.5)ng/L,respectively,which were significantly lower than before treatment(P < 0.05);Serum IL-6 levels after treatment were significantly lower than those of the control group(P<0.05).After treatment,serum TNF-α levels in the observation group and control group were(6.1±2.4)μg/L and(11.3±4.8)μg/L,respectively,which were significantly lower than before treatment(P < 0.05);Serum TNF-α levels after treatment were significantly lower than those of the control group(P <0.05).The effective rate was 84.0%(42/50)in the observation group and 66.0%(33/50)in the control group.The treatment efficiency in the observation group was significantly higher than that in the control group(P < 0.05).No obvious adverse reactions occurred during the treatment of the two groups of patients.Conclusion Thetreatment of acute large-area cerebral infarction with butylphthalide injection can effectively inhibit the inflammatory reaction,improve the neurological function,improve the clinical treatment effect,and have good safety.